Comprehensive Study Guide to Viral Hepatitis and Human Herpesviruses

Clinical Overview of Acute and Chronic Viral Hepatitis

  • Definition & Categorization:

    • Viral hepatitis represents liver parenchymal inflammation caused by primary hepatotropic or systemic viruses.
    • Disease progression is broadly classified into acute infection and chronic infection.

  • Clinical Features of Acute Viral Hepatitis:

    • Preicteric Phase:
      • Malaise
      • Anorexia
      • Nausea
      • Abdominal discomfort
      • Pyrexia (fever)
    • Icteric Phase:
      • Pale stools and dark urine (resulting from bilirubin conjugated clearance alterations)
      • Jaundice (scleral and cutaneous icterus)

  • Clinical Features and Consequences of Chronic Viral Hepatitis:

    • Defined by persistent viral replication and liver inflammation lasting for longer than 6 months.
    • Pathological sequence: Chronic inflammation →\rightarrow progressive liver fibrosis $ ightarrow$ Cirrhosis.
    • Significantly elevated risk of developing Hepatocellular Carcinoma (HCC).

Comparative Virology of Hepatotropic Viruses

  • Primary Hepatotropic Viruses (Hepatitis A, B, C, D, E):

    • Belong to distinct, non-related viral families with varied genome structures, transmission mechanisms, disease courses, diagnostic targets, and preventative measures.
    • Hepatitis A Virus (HAV):
      • Genome & Family: Positive-sense single-stranded RNA (+ve ssRNA+\text{ve ssRNA}) Picornavirus.
      • Transmission: Faecal-oral route; frequently associated with travel abroad.
      • Illness: Acute self-limiting disease only.
      • Cirrhosis / HCC Risk: None.
      • Diagnosis: Hep A IgM antibody.
      • Prevention: Food/water precautions; Inactivated whole virus vaccine.
    • Hepatitis B Virus (HBV):
      • Genome & Family: Partially double-stranded DNA (dsDNA) Hepadnavirus.
      • Transmission: Blood-borne, vertical transmission (mother-to-baby), sexual contact, contaminated needles/sharps.
      • Illness: Acute and chronic illness. Chronicity risk is strictly age-dependent (highest in neonates/infants).
      • Cirrhosis / HCC Risk: Yes.
      • Diagnosis: HBsAg, IgM anti-HBc.
      • Prevention: Passive immunization with Hepatitis B Immunoglobulin (HBIg); Active immunization via recombinant subunit vaccine containing HBsAg.
    • Hepatitis C Virus (HCV):
      • Genome & Family: Positive-sense single-stranded RNA (+ve ssRNA+\text{ve ssRNA}) Flavivirus / Hepacivirus.
      • Transmission: Blood-borne; predominantly via contaminated needles/sharps.
      • Illness: Acute and chronic illness (high rate of progression to chronicity).
      • Cirrhosis / HCC Risk: Yes.
      • Diagnosis: Anti-HCV antibodies, HCV RNA.
      • Prevention: Clean needle exchange and harm-reduction strategies.
    • Hepatitis E Virus (HEV):
      • Genome & Family: Positive-sense single-stranded RNA (+ve ssRNA+\text{ve ssRNA}) Hepevirus.
      • Transmission: Faecal-oral route; in the United Kingdom, predominantly a zoonosis transmitted from pigs (undercooked pork).
      • Illness: Typically acute self-limiting illness in immunocompetent hosts. Exception: Can establish chronic infection in immunosuppressed patients (e.g., solid organ transplant recipients), leading to rapid progression to cirrhosis.
      • Cirrhosis / HCC Risk: No in immunocompetent hosts; Yes in immunosuppressed chronic carriers.
      • Diagnosis: Hep E IgM antibody, HEV RNA.
      • Prevention: Food safety precautions; thoroughly cook pork products.

  • Secondary Hepatotropic Viruses:

    • Systemic viral infections capable of causing acute hepatitis include Epstein-Barr Virus (EBV) and Cytomegalovirus (CMV).
    • Exotic / Viral Hemorrhagic Fever viruses: Yellow Fever virus, Lassa virus, Ebola virus, Marburg virus.

Medical History Taking for Suspected Viral Hepatitis

  • Essential inquiries required during clinical evaluation:
    • Ethnicity and Country of Birth: Screening for high endemicity regions for chronic HBV/HCV.
    • Recent International Travel: Risk assessment for faecal-orally transmitted pathogens (HAV, HEV).
    • Sexual History: New sexual partners or high-risk exposure (HBV).
    • Recreational Drug Use: Direct inquiry into intravenous drug use and shared equipment.
    • Parenteral / Sharps Exposure: Needlestick injuries, tattoos, body piercings, acupuncture.
    • Occupational History: Healthcare workers, sewage/sanitation workers.
    • Medication History: Prescribed medications, hepatotoxic drugs.
    • Blood Product Exposure: Transfusions or blood products received, particularly prior to screening implementation or outside the UK.
    • Alcohol Intake: Quantitative evaluation to identify co-existing alcoholic liver disease.
    • Family History: Specific inquiry regarding chronic liver disease, cirrhosis, or Hepatocellular Carcinoma (HCC).

Hepatitis B Virus (HBV) Structure, Serology, and Clinical Interpretation

  • Viral Structure & Antigens:
    • Discovered in 1965. Enveloped Hepadnavirus containing a partially double-stranded circular DNA genome.
    • HBsAg (Surface Antigen): Surface coat protein found on the outer envelope.
    • HBcAg (Core Antigen): Protein forming the inner nucleocapsid core.
    • HBeAg (e-Antigen): Secreted soluble protein synthesized during active viral replication; functions as an indicator of high viral load and infectivity.

    HBV Viral Structure

  • Diagnostic Markers of Acute Infection:

    • HBsAg Positive: Denotes active HBV infection (acute or chronic).
    • IgM Anti-HBc Positive: Indicates acute or recent infection within the preceding months.

  • Resolved Acute HBV Infection:

    • HBsAg clears from serum (typically within 6 months).
    • IgG Anti-HBc: Remains positive indefinitely as a marker of past natural infection.
    • Anti-HBs: Neutralizing antibody targeting surface antigen; confers immunity.
    • Anti-HBe: Antibody against e-antigen.

  • Chronic HBV Infection:

    • Defined by the persistence of HBsAg in serum for greater than 6 months.
    • HBeAg Positive State: High infectivity (e.g., high risk during needlestick exposure), HBV DNA levels >108 copies/mL> 10^8\,\text{copies/mL}, increased risk of ongoing inflammatory liver disease.
    • Anti-HBe Positive State: Lower infectivity, HBV DNA levels <103 copies/mL< 10^3\,\text{copies/mL}, reduced risk of active inflammatory liver disease.

  • HBV Diagnostic Serology Marker Profiles:

    HBV Diagnostic Serology Table

*   **Acute HBV Infection**: HBsAg (+), IgM anti-HBc (+), IgG anti-HBc (+), HBeAg (+), Anti-HBe (-), Anti-HBs (-).
*   **HBV in the Past (Resolved)**: HBsAg (-), IgM anti-HBc (-), IgG anti-HBc (+), HBeAg (-), Anti-HBe (+), Anti-HBs (+).
*   **Chronic HBV (High Infectivity)**: HBsAg (+), IgM anti-HBc (-), IgG anti-HBc (+), HBeAg (+), Anti-HBe (-), Anti-HBs (-).
*   **Chronic HBV (Low Infectivity)**: HBsAg (+), IgM anti-HBc (-), IgG anti-HBc (+), HBeAg (-), Anti-HBe (+), Anti-HBs (-).
*   **Vaccinated Against HBV**: HBsAg (-), IgM anti-HBc (-), IgG anti-HBc (-), HBeAg (-), Anti-HBe (-), Anti-HBs (+).
  • Clinical Serology Scenario Interpretation:
    • Patient Profile: HBsAg (-), Anti-HBc (-), Anti-HBs (+), Anti-HCV (+), HCV RNA (-).
    • Clinical Conclusion: The presence of Anti-HBs without Anti-HBc confirms successful HBV vaccination. Anti-HCV antibody positivity alongside an undetectable HCV RNA test confirms a cleared past Hepatitis C infection.

Hepatitis C Virus Diagnostic Protocol

  • Anti-HCV Antibody: Serological marker indicating exposure and past infection. It does not differentiate between resolved past infection and active chronic infection.
  • HCV RNA: Direct molecular marker confirming active viral replication.
  • Clinical Diagnostic Pathway: Every individual who tests positive for Anti-HCV must undergo qualitative or quantitative HCV RNA testing to confirm or rule out active infection.

Human Herpesviruses Overview

  • Herpesvirus Family Classification:

    • Herpes Simplex Virus Type 1 (HSV-1)
    • Herpes Simplex Virus Type 2 (HSV-2)
    • Varicella-Zoster Virus (VZV / HHV-3)
    • Epstein-Barr Virus (EBV / HHV-4)
    • Cytomegalovirus (CMV / HHV-5)
    • Human Herpesvirus 6 (HHV-6) →\rightarrow primary cause of febrile exanthem in childhood (roseola infantum)
    • Human Herpesvirus 7 (HHV-7) →\rightarrow primary cause of febrile exanthem in childhood
    • Human Herpesvirus 8 (HHV-8) →\rightarrow etiologic agent of Kaposi's sarcoma

  • Hallmark Feature:

    • ALL human herpesviruses exhibit latency. Primary infection is followed by lifelong persistence in host sensory ganglia or lymphoid cells, maintaining the potential for reactivation (secondary / recurrent infection).

Herpes Simplex Virus (HSV)

  • Primary Infection Outcomes:

    • 90% of primary infections are completely asymptomatic.
    • 9% result in minor, non-specific clinical illness.
    • 1% present as severe primary clinical disease.

  • Clinical Manifestations of Primary HSV Disease:

    • Gingivostomatitis (Orolabial Herpes): Ulcerative, painful vesicular lesions involving the lips, buccal mucosa, tongue, and gums.

        Gingivostomatitis

*   **Herpetic Keratitis**: Corneal infection classically presenting with dendritic corneal ulcers.

        Herpetic Keratitis

*   **Genital Herpes**: Primary eruption of painful clustered vesicles and shallow ulcers on the genitalia. Note that the vast majority of genital HSV infections are asymptomatic.

        Primary Genital Herpes

*   **Eczema Herpeticum**: Severe, widespread viral superinfection occurring over pre-existing skin barrier breakdown (e.g., atopic eczema).

        Eczema Herpeticum

*   **Neonatal Herpes**: Viral acquisition occurring intrapartum during passage through an infected birth canal.

        Neonatal Herpes Eruption

    *   *Gestational Distribution*: 80% premature infants, 20% full-term infants.
    *   *Clinical Outcomes*:
        *   50% present with localized mucocutaneous disease (skin, mouth, eyes) →\rightarrow full recovery.
        *   50% present with disseminated disease targeting the brain, liver, and lungs, or isolated neurological disease →\rightarrow 70% mortality rate; 30% survival rate (with the majority of survivors suffering permanent neurological or ocular damage).

            Neonatal Herpes Disease Prognosis

*   **Herpes Simplex Encephalitis (HSE)**: Acute necrotizing viral encephalitis localized to the temporal lobes, resulting in focal hemorrhagic necrosis.

        Herpes Simplex Encephalitis Hemorrhagic Necrosis

*   **Herpetic Whitlow**: Lesion located around the nail bed or fingertip.

        Herpetic Whitlow

  • Pathogenesis of Latency and Recurrence:
    • Primary mucosal infection $ ightarrow$ retroaxonal transport along sensory nerves $ ightarrow$ viral latency established in sensory nerve ganglia (e.g., trigeminal ganglion for oral lesions; sacral ganglia for genital lesions).
    • Reactivation triggers $ ightarrow$ anterograde axonal movement back to mucocutaneous site $ ightarrow$ localized recurrent lesions (e.g., herpes labialis / cold sore).

    HSV Primary Infection Latency and Recurrence Pathway

    Recurrent Oral Herpes Cold Sore

  • HSV Diagnostics:

    • Cutaneous / Mucosal Lesions: Swab lesion base by vigorously scraping cells from the vesicle floor.
    • Suspected Encephalitis: Cerebrospinal Fluid (CSF) lumbar puncture.
    • Assay: Viral DNA genome detection via Polymerase Chain Reaction (PCR).

  • HSV Antiviral Therapeutics:

    • Aciclovir (Acycloguanosine):
      • Nucleoside analogue requiring tri-phosphorylation.
      • The first phosphorylation step is exclusively executed by virally encoded thymidine kinase.
      • Cellular enzymes execute subsequent steps to form aciclovir triphosphate, which competitively inhibits viral DNA polymerase and terminates DNA chain elongation.
    • Valaciclovir: L-valine ester prodrug of aciclovir providing superior oral bioavailability.

Varicella-Zoster Virus (VZV)

  • Primary Infection: Chickenpox (Varicella):
    • Generalized pruritic maculopapular, vesicular, and crusting eruption appearing in successive crops.

    Chickenpox Eruption

*   *Complications*: **Varicella pneumonitis** represents the most common life-threatening complication of primary chickenpox in adult patients.

    Varicella Pneumonitis

  • Latency and Reactivation: Herpes Zoster (Shingles):
    • Following primary varicella, VZV travels to the dorsal root ganglia or cranial nerve ganglia where latency is established.
    • Reactivation results in Herpes Zoster (shingles), presenting as a painful vesicular eruption restricted to a sensory dermatome.

    VZV Latency and Zoster Diagram

    Herpes Zoster Dermatomal Rash

  • Risk Factors for Zoster Reactivation:

    • Increasing age
    • Preceding acute systemic illness or physical stress
    • Ultraviolet light exposure
    • Surgical trauma
    • Immunosuppressive conditions or treatments: HIV infection, active malignancies, solid organ/stem cell transplant recipients, chemotherapy, radiotherapy, systemic corticosteroids.
    • Associated Malignancies: Lymphoreticular malignancies are most frequently linked to zoster reactivation, including Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Chronic Lymphocytic Leukaemia (CLL), and Multiple Myeloma. Unusually severe or multi-dermatomal zoster should raise clinical suspicion for an underlying undiagnosed malignancy.

  • Complications of Herpes Zoster:

    • Post-Herpetic Neuralgia (PHN): Severe persistent neuropathic pain lasting months after rash resolution; risk increases significantly with age.
    • Neurological Complications: Motor nerve root involvement causing peripheral motor weakness.
    • Ocular Complications: Ophthalmic zoster (involving the V1V_1 branch of the trigeminal nerve) and Zoster keratitis.

    Ophthalmic Zoster

*   **Complications in Immunocompromised Patients**: Disseminated zoster, Zoster encephalitis, Zoster hepatitis, Zoster pneumonitis; carries high mortality risk.
  • VZV Diagnostics & Treatment:
    • Diagnosis: Swab base of fresh vesicle for PCR genome detection.
    • Treatment: Aciclovir (administered at significantly higher dosages than for HSV due to lower enzyme binding affinity of VZV thymidine kinase).

Epstein-Barr Virus (EBV)

  • Pathogenesis & Cellular Tropism:

    • EBV selectively infects resting B lymphocytes, driving their transformation into immortalized lymphoblastoid cell lines.
    • Leads to production of human monoclonal antibodies and creates a substrate for B-cell lymphoproliferative disorders and malignancies.

  • Infectious Mononucleosis (Glandular Fever):

    • Clinical Triad: Fever, Pharyngitis (severe exudative tonsillitis), Cervical and generalized Lymphadenopathy.

    Pharyngitis in Infectious Mononucleosis

*   **Syndromic Differential**: Infectious Mononucleosis is a clinical syndrome. Beyond primary EBV infection, identical presentations can be caused by: Cytomegalovirus (CMV), *Toxoplasma gondii*, and HIV seroconversion illness.
  • Atypical Mononuclear Cells:
    • Blood smears demonstrate characteristic large atypical mononuclear cells.
    • Cellular Identity: These atypical mononuclear cells are activated CD8+ cytotoxic T lymphocytes proliferating in response to EBV-infected B cells.

    Atypical Mononuclear Cells Peripheral Blood Smear

  • Complications of Infectious Mononucleosis:

    • Acute upper respiratory tract obstruction secondary to massive tonsillar enlargement.
    • Splenic rupture (splenomegaly predisposes to traumatic rupture; physical exertion must be avoided).
    • Hepatitis.

  • EBV Diagnostic Testing:

    • Monospot Test: Heterophile antibody detection via sheep or horse red blood cell agglutination.
    • Serology: Detection of specific EBV IgM antibodies.
    • Molecular: PCR genome detection in throat swabs or EDTA blood samples.

  • Malignancies Associated with EBV:

    • Post-Transplant Lymphoproliferative Disorder (PTLD)
    • Burkitt's Lymphoma
    • Nasopharyngeal Carcinoma
    • Hodgkin's Lymphoma (specific histological subtypes)

Cytomegalovirus (CMV)

  • Clinical Profile:
    • Typically asymptomatic or self-limiting in immunocompetent hosts.
    • Capable of presenting as a heterophile-antibody negative Infectious Mononucleosis syndrome.
    • Major multi-system pathogen in specific vulnerable groups:
      1. Fetus (Congenital CMV): Most common congenital viral infection worldwide (~1 in 300 live births). Features include intrauterine growth restriction, hepatosplenomegaly, jaundice, microcephaly, sensorineural hearing loss, and petechial/purpuric rash.

        Congenital CMV Manifestations

    2.  **Immunosuppressed Patients**: Solid organ/bone marrow transplant recipients, advanced HIV infection. Causes sight-threatening retinitis, pneumonitis, colitis, and hepatitis.

  • CMV Diagnostic Procedures:

    • Serology: CMV IgM antibodies.
    • Systemic Infection: EDTA blood sample for PCR viral genome detection.
    • Congenital Infection: PCR genome detection performed specifically on a urine sample within the first weeks of life.

  • CMV Antiviral Therapeutics & Pharmacology:

    • Aciclovir DOES NOT work against CMV because CMV lacks a virally encoded thymidine kinase required for the initial activation step.
    • Effective Antiviral Drugs: Ganciclovir / Valganciclovir, Cidofovir, Foscarnet.
    • Mechanism: All act as direct inhibitors of viral DNA synthesis.
    • Toxicity Profile: All exhibit higher toxicity and adverse event profiles (such as myelosuppression or nephrotoxicity) compared to aciclovir.

Pharmacology and Viral Resistance Principles

  • Aciclovir Pharmacology Review:
    • Selective activity against DNA herpesviruses (HSV, VZV).
    • Requires initial phosphorylation by viral thymidine kinase to convert to aciclovir monophosphate.
    • Inhibits viral DNA polymerase after conversion to the active triphosphate form.
  • Mechanisms of Resistance:
    • Viral resistance to aciclovir develops primarily through genetic mutations in the viral thymidine kinase (TK) gene or mutations in the viral DNA polymerase gene.